Comparative assessment of the efficacy and safety of add ontreatment with Sofosbuvir standard of care therapeutic regimenVelpatasvir” to standard of caretherapeutic regimen” in patients with COVID-19

Phase 3

Recruiting

• Conditions: COVID-19.; COVID-19 disease; U07.1

• Registration Number: IRCT20130812014333N145
• Lead Sponsor: Kermanshah University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 18 May 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

Age over 18 years
Absolute lymphocyte count <1100 / ML or SaO2 <93

Exclusion Criteria

Pregnancy or breast-feeding
The physician's decision that the trial is not in the patient's interest
Any circumstances that do not allow to follow the treatment protocol easily
A history of severe liver disease including cirrhosis or ALT or AST levels more than fives times normal
Drugs that are contraindicated with standard treatment or Sofosbuvir-Velpatasvir and cannot be discontinued
History of untreated HIV infection or hepatitis C

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Clinical status. Timepoint: Beginning of the study, 10 days later, or discharge time. Method of measurement: By a doctor.